NCT05526742View on ClinicalTrials.gov

A Study to Evaluate the Relative Bioavailability of Formulations of CKD-510 and to Assess the Effect of Food on the CKD-510 Tablet Formulation in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 24, 2022

Primary Completion Date

September 13, 2022

Study Completion Date

September 13, 2022

Conditions
Healthy Volunteers
Interventions
DRUG

CKD-510 capsule (reference)

Single-dose of CKD-510 will be administered as oral capsule in a fasted state.

DRUG

CKD-510 tablet (test)

Single-dose of CKD-510 will be administered as oral tablet in a fasted state.

DRUG

CKD-510 tablet (test)

Single-dose of CKD-510 will be administered as oral tablet in a fed state.

Trial Locations (1)

45227

Clinical Pharmacology Unit, Cincinnati

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY